公开(公告)号：US08481497B2

公开(公告)日：2013-07-09

申请号：US12601811

申请日：2008-05-29

申请人： Kohzoh Imai ,  Shigeru Sasaki ,  Tsutomu Seito

发明人： Kohzoh Imai ,  Shigeru Sasaki ,  Tsutomu Seito

IPC分类号： A61K38/00 ,  A61K39/395 ,  A61K39/44 ,  A61K38/21 ,  A61P35/00

CPC分类号： C07K16/2863 ,  A61K9/127 ,  A61K31/351 ,  A61K31/53 ,  A61K35/15 ,  A61K35/17 ,  A61K38/212 ,  A61K38/215 ,  A61K39/395 ,  A61K45/06 ,  A61K2300/00

摘要： [PROBLEMS] To provide a technique which enables an effective antibody therapy for cancer which targets for FGFR1 without the need of using any effective antibody having high specificity and a potent cell-killing activity. [MEANS FOR SOLVING PROBLEMS] Disclosed are: a therapeutic agent for cancer, which comprises an enhancer of the expression of a fibroblast growth factor receptor-1 and an anti-fibroblast growth factor receptor-1 antibody; and a method for the treatment of cancer using the therapeutic agent.

摘要翻译： [问题]提供一种能够对靶向FGFR1的癌症进行有效的抗体治疗的技术，而不需要使用任何具有高特异性和强效细胞杀伤活性的有效抗体。 解决问题的方法公开了一种癌症治疗剂，其包含成纤维细胞生长因子受体-1的表达增强子和抗成纤维细胞生长因子受体-1抗体; 以及使用该治疗剂治疗癌症的方法。

公开(公告)号：US20120264120A1

公开(公告)日：2012-10-18

申请号：US13407645

申请日：2012-02-28

申请人： MINORU TOYOTA ,  Mutsumi Toyota ,  EIICHIRO YAMAMOTO ,  SEIKO KAMIMAE ,  SUZUKI HIROMU ,  HIROO YAMANO

发明人： MINORU TOYOTA ,  Mutsumi Toyota ,  EIICHIRO YAMAMOTO ,  SEIKO KAMIMAE ,  SUZUKI HIROMU ,  HIROO YAMANO

IPC分类号： C12Q1/68 ,  G01N33/48

CPC分类号： G01N33/57419 ,  A61B1/041 ,  C12Q1/6886 ,  C12Q2600/154 ,  C12Q2600/178 ,  G01N33/57488

摘要： An object of the present invention is to provide a method for non-invasively diagnosing invasiveness or degree of invasion of colorectal tumors.The present invention is characterized in that it enables to obtain a specimen that can be used to detect invasive colorectal tumors by spraying a washing fluid onto the colonic mucous layer of a subject to detach the mucus from the mucous layer, and collecting the detached mucus together with the washing fluid.

摘要翻译： 本发明的目的是提供非侵入性地诊断结肠直肠肿瘤侵袭性或侵袭程度的方法。 本发明的特征在于，其能够获得可以用于通过将洗涤液喷洒到受试者的结肠粘膜层上来检测侵入性结肠直肠肿瘤的样品，以从粘液层分离粘液，并将分离的粘液收集在一起 与洗涤液。

公开(公告)号：US08216152B2

公开(公告)日：2012-07-10

申请号：US12449816

申请日：2008-02-12

申请人： Gohichi Tanaka ,  Yukihiro Sawada

发明人： Gohichi Tanaka ,  Yukihiro Sawada

IPC分类号： A61B5/02

CPC分类号： A61B5/022 ,  A61B5/02007 ,  A61B5/02116 ,  A61B5/1455

摘要： PROBLEMS TO BE SOLVED: A finger arterial elasticity measuring program, a finger arterial elasticity measuring device and a finger arterial elasticity measuring method are provided for making it possible to measure an elasticity index of a finger artery in accordance with a pulse wave of a finger artery without measuring a blood pressure in evaluating the elasticity of the finger artery related to the degree of arterial sclerosis in an easy and least expensive manner.MEANS FOR SOLVING THE PROBLEMS: A computer functioning by a finger arterial elasticity measuring program includes a pulse wave data memory unit 42, a cuff pressure data memory unit 43, a normalized pulse volume (NPV) calculating unit 52 for dividing an amplitude (ΔI) of an alternate component of a pulse wave by an average value of direct components (I) to calculate NPV, a relative cuff pressure (Pr) calculating unit 53 for calculating a difference between a cuff pressure at the maximum amplitude of the pulse wave and each cuff pressure as Pr, an FEI calculating unit 54 for calculating a linear regression slope (n) of the following expression (1) as an elasticity index of a finger artery: ln(NPV)=ln(bn)−n·Pr . . . (1) where b is a constant.

摘要翻译： 要解决的问题：提供手指动脉弹性测量程序，手指动脉弹性测量装置和手指动脉弹性测量方法，用于根据手指动脉的脉搏波测量手指动脉的弹性指数 在以简单且最便宜的方式评估与动脉硬化程度相关的手指动脉的弹性时不测量血压。 用于解决问题的手段：通过手指动脉弹性测量程序起作用的计算机包括脉波数据存储单元42，袖带压力数据存储单元43，用于将振幅（＆Dgr; I）的脉冲波的替代分量乘以直接分量（I）的平均值来计算NPV，相对袖带压力（Pr）计算单元53，用于计算脉搏波的最大幅度的袖带压力之间的差值 并且每个袖带压力为Pr，FEI计算单元54，用于计算作为手指动脉的弹性指数的以下表达式（1）的线性回归斜率（n）：ln（NPV）= ln（bn）-n·Pr 。 。 。 （1）其中b是常数。

公开(公告)号：US20110130341A1

公开(公告)日：2011-06-02

申请号：US12991335

申请日：2009-05-07

申请人： Hiromu Suzuki ,  Minoru Toyota ,  Kohzoh Imai ,  Yasuhisa Shinomura ,  Takashi Tokino

发明人： Hiromu Suzuki ,  Minoru Toyota ,  Kohzoh Imai ,  Yasuhisa Shinomura ,  Takashi Tokino

IPC分类号： A61K38/17 ,  C12Q1/68 ,  C07H21/00 ,  C07K14/47 ,  C07H21/02 ,  A61K31/7088 ,  A61P35/00

CPC分类号： C12Q1/6886 ,  A61K31/7105 ,  A61K31/711 ,  C07K14/47 ,  C12N15/113 ,  C12N2310/141 ,  C12N2320/10 ,  C12N2330/10 ,  C12Q2600/118 ,  C12Q2600/154 ,  C12Q2600/178

摘要： The object aims to comprehensively analyze miRNA that undergoes epigenetic silencing in cancer to identify miRNA associated with cancer, elucidate the role of the identified miRNA in cancer, and develop a novel method for detecting cancer and a novel therapeutic agent for cancer both of which relate to the miRNA. Disclosed is a method for detecting cancer in a subject, which comprises detecting methylated CpG in a CpG island located in a promoter region of a microRNA 34b gene and/or a microRNA 34c gene in a biological sample collected from the subject. Also disclosed is a therapeutic agent for cancer, which comprises a nucleic acid encoding a BTG4 gene or BTG4, or comprises a nucleic acid encoding a miR-34b gene and/or an miR-34c gene or miR-34b and/or miR-34c.

摘要翻译： 该目的旨在全面分析在癌症中经历表观遗传学沉默的miRNA，以鉴定与癌症相关的miRNA，阐明鉴定的miRNA在癌症中的作用，并开发出一种检测癌症的新方法和一种用于癌症的新型治疗剂，涉及 miRNA。 公开了一种用于检测受试者中癌症的方法，其包括检测位于从受试者收集的生物样品中的微小RNA 34b基因和/或微小RNA 34c基因的启动子区域中的CpG岛中的甲基化CpG。 还公开了一种癌症治疗剂，其包含编码BTG4基因或BTG4的核酸，或包含编码miR-34b基因和/或miR-34c基因或miR-34b和/或miR-34c的核酸 。

公开(公告)号：US20220133805A1

公开(公告)日：2022-05-05

申请号：US17438833

申请日：2020-03-13

申请人： Sapporo Medical University ,  Nipro Corporation

发明人： Osamu HONMOU ,  Masanori SASAKI ,  Yuko SASAKI ,  Shinichi OKA ,  Masahito NAKAZAKI ,  Rie MAEZAWA

IPC分类号： A61K35/28 ,  A61P25/28 ,  A61K35/15 ,  A61P21/02

摘要： The present invention relates to a pharmaceutical composition for treating amyotrophic lateral sclerosis. More specifically, the present invention relates to a pharmaceutical composition for treating amyotrophic lateral sclerosis, wherein the pharmaceutical composition comprises mesenchymal stem cells and is intravenously administered.

公开(公告)号：US11028136B2

公开(公告)日：2021-06-08

申请号：US15514169

申请日：2015-09-24

申请人： Sapporo Medical University ,  Medical & Biological Laboratories Co., Ltd.

发明人： Toshihiko Torigoe ,  Eri Atsuyama ,  Hironori Otaka ,  Kazue Nakano ,  Dongliang Li ,  Shingo Toji ,  Takuya Asano ,  Ryota Horibe ,  Yoshihiko Hirohashi ,  Noriyuki Sato ,  Tsuyoshi Saito

IPC分类号： A61K35/17 ,  C12N5/0783 ,  C07K14/47 ,  C12N15/63 ,  A61K48/00 ,  C12N15/09 ,  A61K35/76 ,  C12N15/00 ,  C12N5/10 ,  A61K39/00 ,  C07K7/06 ,  C07K14/74 ,  C07K16/18 ,  C07K16/30 ,  C12N5/078 ,  G01N33/574 ,  C07K14/82

摘要： The object is to provide a tumor antigen peptide that is specifically presented on a cancer and a cancer stem cell, and a pharmaceutical composition, etc. that is useful for the prevention and/or treatment of a cancer and contains the above peptide as an active ingredient.
The above object has been accomplished by providing a BORIS-derived partial peptide belonging to isoform A or C or subfamily 5 or 6, a polynucleotide encoding the peptide, a pharmaceutical composition containing the above as an active ingredient, and an agent for the prevention and/or treatment of a cancer, the agent containing the above as an active ingredient and inducing CTLs.

公开(公告)号：US20190255118A1

公开(公告)日：2019-08-22

申请号：US16404671

申请日：2019-05-06

申请人： Sapporo Medical University

发明人： Osamu Honmou

IPC分类号： A61K35/28 ,  A61K35/16 ,  C12N5/0775

摘要： The present invention relates to a method for growing, rapidly and massively ex vivo, cells collected from a living subject to provide a safe and effective pharmaceutical preparation for biological tissue repair/regeneration. Specifically, the present invention relates to a method for growing cells in a sample collected from a living subject by culturing the cells in a medium containing allogeneic (including autogenic) serum. Preferably the allogeneic serum has been determined as being negative for a serum tumor marker and/or an infectious factors, and the amount of the anticoagulant (e.g., heparin, a heparin derivative, or a salt thereof) added to the collected sample is less than 5 U/mL with respect to the volume of the sample or the amount of the anticoagulant in the medium at the start of culture is less than 0.5 U/mL. The present invention further relates to use of the method.

公开(公告)号：US20190183937A1

公开(公告)日：2019-06-20

申请号：US16325889

申请日：2017-04-13

申请人： Sapporo Medical University ,  Nipro Corporation

发明人： Osamu Honmou ,  Masanori Sasaki ,  Yuko Sasaki ,  Rie Maezawa ,  Shinichi Oka ,  Masahito Nakazaki

IPC分类号： A61K35/28

CPC分类号： A61K35/28 ,  A61K2035/124 ,  A61P9/10 ,  A61P25/00 ,  A61P25/28 ,  A61P43/00

摘要： The present invention relates to a life extension agent containing CD24-negative mesenchymal stem cells and the treatment of dementia, cerebral infarction, spinal cord injury and the like using the life extension agent.

公开(公告)号：USD836210S1

公开(公告)日：2018-12-18

申请号：US29610745

申请日：2017-07-14

申请人： Sapporo Medical University ,  NIPRO CORPORATION

设计人： Osamu Honmou ,  Tomohiro Uchimura ,  Kei Matsuo ,  Yoshihiro Yoshikawa ,  Yoshihito Yamagata ,  Masayuki Ishigami

公开(公告)号：US20180078679A1

公开(公告)日：2018-03-22

申请号：US15556776

申请日：2016-03-07

申请人： THE CHEMO-SERO-THERAPEUTIC RESEARCH INSTITUTE ,  ADEKA CORPORATION ,  NATIONAL UNIVERSITY CORPORATION TOKYO MEDICAL AND DENTAL UNIVERSITY ,  SAPPORO MEDICAL UNIVERSITY

发明人： Hideki SAGA ,  Takanori UCHIDA ,  Shoko TOKOROZAKI ,  Ken-ichiro HIWATARI ,  Haruki OBARA ,  Akio KISHIDA ,  Tsuyoshi KIMURA ,  Jun NEGISHI ,  Tetsuya HIGAMI ,  Seiichi FUNAMOTO

IPC分类号： A61L31/04

CPC分类号： A61L31/046 ,  A61L24/106 ,  A61L31/005 ,  A61L31/10 ,  A61L2300/424

摘要： An anti-adhesion material comprising decellularized tissues and a biocompatible polymer or fibrin glue; a method for preparing an anti-adhesion material comprising complexing a biocompatible polymer or fibrin glue to decellularized tissues; an anti-adhesion material kit comprising decellularized tissues and a biocompatible polymer or fibrin glue; a substitute biomembrane comprising decellularized tissues and a biocompatible polymer or fibrin glue; a method for preparing a substitute biomembrane comprising complexing a biocompatible polymer or fibrin glue to decellularized tissues; and a substitute biomembrane kit comprising decellularized tissues and a biocompatible polymer or fibrin glue.